Last reviewed · How we verify
MSC2364447C
At a glance
| Generic name | MSC2364447C |
|---|---|
| Also known as | M2951, Evobrutinib |
| Sponsor | EMD Serono Research & Development Institute, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- Atrioventricular block second degree
- Ventricular extrasystoles
- Diarrhoea
- Blood pressure increased
- Paraesthesia
- Ventricular tachycardia
- Conjunctivitis
- Nasopharyngitis
- Periorbital haematoma
- Lipase increased
- Arthralgia
Key clinical trials
- A TQT Study of Effect of M2951 on Cardiac Repolarization (PHASE1)
- Drug-drug Interaction Study of Evobrutinib With Midazolam in Healthy Participants (PHASE1)
- Effect of Renal Impairment on Evobrutinib Pharmacokinetics (PK) (PHASE1)
- MSC2364447C Phase 1b in Systemic Lupus Erythematosus (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |